Keywords: Alzheimer's disease, Drug market forecasts, Patent expiries, R&D activity, Frost & Sullivan

European Alzheimer's drug market to grow to $4.78 billion by 2019, says F&S

Article | 25 November 2012

Print This

The patent expiry of all four existing European Medicines Agency-approved drugs for Alzheimer's disease (AD) by 2015 is likely to cause ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in